Alvine Pharmaceuticals, Inc. Lands $70 Million From AbbVie (ABBV) for Celiac Disease Drug
5/14/2013 10:09:01 AM
More...
|
AbbVie (ABBV) and Alvine Pharmaceuticals, Inc. to Collaborate on Investigational Oral Therapy for Celiac Disease
5/14/2013 9:50:35 AM
More...
|
Alvine Pharmaceuticals, Inc. Presents Celiac Disease Symptom Frequency and Severity Study Results at the 2012 American College of Gastroenterology Meeting
10/24/2012 9:18:31 AM
More...
|
Alvine Pharmaceuticals, Inc. ALV003 Receives Fast Track Designation From the FDA for the Potential Treatment of Celiac Disease
9/5/2012 9:32:28 AM
More...
|
Alvine Pharmaceuticals, Inc.'s ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover Information Inc. for a Rare Second Year
11/29/2011 10:07:27 AM
More...
|
Alvine Pharmaceuticals, Inc. Presents Additional Efficacy Data From Phase 2a Trial of ALV003 in Celiac Disease Patients
10/24/2011 9:04:01 AM
More...
|
Alvine Pharmaceuticals, Inc. Announces Positive Results From Phase 2a Trial of ALV003 in Celiac Disease Patients
10/11/2011 7:03:58 AM
More...
|
Alvine Pharmaceuticals, Inc. Announces Upcoming Presentation of Phase 2a ALV003 Data in Patients With Celiac Disease
9/22/2011 8:57:20 AM
More...
|
Alvine Pharmaceuticals, Inc. Appoints James D. Watson as Senior Vice President and Chief Business Officer
9/13/2011 10:25:00 AM
More...
|
Alvine Pharmaceuticals, Inc. Announces Issuance of US Patents for Enzyme Use in Celiac Disease
5/18/2011 9:45:42 AM
More...
|
|